Marina I. Salvadori

Marina I. Salvadori

Auto-generated profile, based on publicly available information

Marina I. Salvadori

Centre for Immunization Surveillance and Programs Public Health Agency of Canada Ottawa ON Canada

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in American Journal of Infection Control
Verified
Journal Article
Closed access
MLMarie-Astrid Lefebvre
Marie-Astrid Lefebvre
EREwa Rajda
Ewa Rajda
CFCharles Frenette
Charles Frenette
FPFrance Paquet
France Paquet
EREarl Rubin
Earl Rubin
MSMarina I. Salvadori
Marina I. Salvadori

8 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
RMRafael N. Miranda
Rafael N. Miranda
ASAlison E. Simmons
Alison E. Simmons
MLMichael W.Z. Li
Michael W.Z. Li
GGGebremedhin B. Gebretekle
Gebremedhin B. Gebretekle
MXMin Xi
Min Xi
ATAshleigh Tuite
Ashleigh Tuite
Background: With shifting epidemiology and changes in the vaccine funding landscape, resource use considerations for ongoing COVID-19 vaccination programs are increasingly important. We assessed the cost-effectiveness of COVID-19 vaccination programs, where eligibility is defined by combinations of age and chronic medical conditions, including a strategy similar to current Canadian recommendations, from the health system and societal perspectives. Methods: We used a static, individual-based probabilistic model simulating medically attended COVID-19 in a population of 1 million people followed over a 15-month time period to estimate costs in 2023 Canadian dollars, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs), discounted at 1.5%. COVID-19 epidemiology, vaccine characteristics, and costs were based on the most recently available data. Results: Annual vaccination for adults aged 65 years and older consistently emerged as a cost-effective intervention, with ICERs less than $50,000 per QALY compared to no vaccination for a range of model assumptions. Adding a second dose for adults aged 65 years and older or expanding programs to include vaccination for younger age groups, including those at higher risk of COVID-19 due to chronic medical conditions, generally resulted in ICERs of greater than $50,000 per QALY. Shifting timing of vaccination programs to better align with periods of high COVID-19 case occurrence could result in biannual vaccination for those aged 65 and older being a cost-effective strategy. Conclusions: COVID-19 vaccination programs may be cost-effective when focused on groups at higher risk of disease. Optimal timing of vaccination could improve the cost-effectiveness of various strategies.

30 October 2025 in Eurosurveillance
Verified
Journal Article
Open access
SWSarah E Wilson
Sarah E Wilson
VZVanessa Zubach
Vanessa Zubach
BLBrendan Lew
Brendan Lew
MHMaan Hasso
Maan Hasso
RORomy Olsha
Romy Olsha
JHJoanne Hiebert
Joanne Hiebert
We report a case of a mild, self-limited rash illness in a child 18 days after measles-mumps-rubella-varicella vaccination. Initial testing with a PCR-based method failed to detect vaccine virus. Sequencing later identified a novel mutation in the probe-binding site of the vaccine assay that had arisen after vaccination and resulted in the false-negative PCR test results.

14 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
ASAlison E. Simmons
Alison E. Simmons
RMRafael N. Miranda
Rafael N. Miranda
MLMichael W.Z. Li
Michael W.Z. Li
GGGebremedhin B. Gebretekle
Gebremedhin B. Gebretekle
MXMin Xi
Min Xi
ATAshleigh Tuite
Ashleigh Tuite
Background: As COVID-19 becomes established as an endemic disease with widespread population immunity, there is uncertainty about the economic benefit of ongoing COVID-19 vaccination programs. We assessed the cost-effectiveness of a COVID-19 vaccination program similar to current Canadian recommendations, modelled as annual vaccination for people aged less than 65 years with chronic medical conditions and biannual vaccination for adults aged 65 years and older. Methods: Using a static individual-based model of medically attended COVID-19 in a population of 1 million people, we estimated costs (in 2023 Canadian dollars), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). We used health system and societal perspectives and a 1.5% discount rate. Parameters were based on recent COVID-19 epidemiology, vaccine characteristics, and costs. Results: Between July 2024 and September 2025, a program similar to current Canadian recommendations was estimated to avert 3.1% (95% credible interval (CrI): 3.0 to 3.2%) of outpatient cases, 8.8% (95% CrI: 7.3 to 10.4%) of inpatient cases, 3.6% (95% CrI: 2.8 to 4.3%) of PCC cases, and 9.4% (95% CrI: 5.6 to 13.8%) of deaths compared to no vaccination. The number needed to vaccinate to prevent one hospitalization and one death was 1,121 (95% CrI: 941 to 1,357) and 8,656 (95% CrI: 5,848 to 14,915), respectively. For the health system perspective, the program would cost an additional $4.695 million but result in 221.17 QALYs gained, leading to an ICER of $21,227 per QALY compared to no vaccination. Vaccine price influenced cost-effectiveness, with higher prices reducing the likelihood the program met common cost-effectiveness thresholds. Conclusions: A program similar to current COVID-19 recommendations in Canada is likely effective and cost-effective compared to no vaccination. However, unlike some other research studies, alternate vaccination strategies that may offer better value for money were not evaluated.

27 June 2022 in Paediatrics & Child Health
Verified
Journal Article
Open access
PDF file
AAAhmed Almadani
Ahmed Almadani
CKChristos Karatzios
Christos Karatzios
DDDubravka Diksic
Dubravka Diksic
MSMarina Salvadori
Marina Salvadori
An 11-year-old previously healthy and vaccinated female presented to our centre with a 2-day history of left foot edema associated with tenderness, erythema, and inability to bear weight on the affected foot. She had no fever. She was seen in an outpatient clinic 2 days prior to her presentation and started on oral cephalexin; however, her symptoms worsened and erythema had ascended rapidly. On examination, she was clinically well and afebrile. Puncture wound was present between her left fourth and fifth toe with a large amount of white watery discharge coming through the wound. She had significant pitting edema and erythema of her left foot extending up to left distal tibia with warmth, tenderness, and normal ankle joint range of motion ( Figure 1). Her initial blood work showed a white blood cell count of 12.4 × 109/L, with an absolute neutrophil count of 7.6 ×...

1 June 2012 in Paediatrics & Child Health
Verified
Journal Article
Open access
PDF file
MSMarina Salvadori
Marina Salvadori
WFWilliam Fisher
William Fisher
Marina Salvadori, MD FRCPC, William Fisher, Ph. D.; La vaccination contre le méningocoque : des lignes directrices et le problème du taux de vaccination, Paedi